Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/08/2019 | 01:32am EDT

By Nathan Allen

Sanofi said Monday that it has concluded the research-and-option phase of its rare-disease alliance with Alnylam Pharmaceuticals

Through the alliance, which was set up in 2014, the companies developed a treatment for patients with ATTR amyloidosis and are testing a molecule to treat hemophilia, Sanofi said.

In the new phase of the alliance Alnylam will proceed with another early-stage therapy for an undisclosed rare disease, taking it through to initial trials.

Sanofi said it will then be responsible for any further development of the therapy, paying royalties to Alnylam from global sales.

The two companies have amended their equity agreement, with France's Sanofi obtaining a release from its lock-up of trading in Alnylam's shares.

Write to Nathan Allen at nathan.allen@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
ALNYLAM PHARMACEUTICALS, INC. 3.05% 67.87 Delayed Quote.-6.91%
SANOFI 0.15% 73.8 Delayed Quote.-1.93%
SANOFI -0.08% 73.9 Real-time Quote.-2.26%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
06:47aCEGEDIM : and Sanofi are engaged in an innovative collaboration on Real World Da..
AQ
04:39aCEGEDIM : and Sanofi are engaged in an innovative collaboration on Real World Da..
AQ
02:48aSANOFI : French Deal Spree Fueled By Easy Money
DJ
05/21SANOFI : France Goes on Deal Spree, Thanks to ECB Easy Money
DJ
05/17REGENERON PHARMACEUTICALS : Updated Libtayo Results Reinforce Durable and Substa..
AQ
05/17SANOFI : - Updated Libtayo Results Reinforce Durable and Substantial Response Ra..
AQ
05/17PFIZER : new JAK inhibitor could come after your eczema market
AQ
05/16SANOFI : oncology pipeline targeting various cancers highlighted at ASCO 2019
AQ
05/15PRINCIPIA BIOPHARMA : Announces First Patient Dosed in Sanofis Phase 2b Trial of..
AQ
05/11SANOFI : gets EC approval for Dupixent to treat severe asthma
AQ
More news
Financials (€)
Sales 2019 36 099 M
EBIT 2019 8 991 M
Net income 2019 5 019 M
Debt 2019 14 487 M
Yield 2019 4,28%
P/E ratio 2019 17,44
P/E ratio 2020 15,28
EV / Sales 2019 2,98x
EV / Sales 2020 2,79x
Capitalization 92 933 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 83,5 €
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-2.26%103 648
JOHNSON & JOHNSON7.26%367 513
PFIZER-4.72%231 237
ROCHE HOLDING LTD.9.70%226 519
NOVARTIS12.54%207 417
MERCK AND COMPANY4.04%203 088